NCNA

MKT CAP:$13M

NuCana plc

Market Cap

$13M

Healthcare·Biotechnology·🇬🇧 United Kingdom·NASDAQ

Healthcare·Biotechnology·🇬🇧·NASDAQ

Stock Price

$2.13-$1.51 (-41.48%)

Apr 22, 2026

Company Details

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes A...

CEO

Hugh Stephen Griffith

IPO Date

Sep 28, 2017

Website

www.nucana.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$40M

EPS (Diluted)

-$141.21

Free Cash Flow

-$10M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 19, 2026

$0EPS -$10.45

Q4 2025

Mar 19, 2026

$0EPS -$0.89

Q3 2025

Nov 13, 2025

$0EPS -$0.10

Q2 2025

Aug 20, 2025

$0EPS -$5.39

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$14M
Q2 22	$0	$0	-$7M
Q3 22	$0	$0	-$8M
Q4 22	$0	$0	-$20M
Q1 23	$0	$0	-$12M
Q2 23	$0	$0	-$8M
Q3 23	$0	$0	-$11M
Q4 23	$0	$0	-$12M
Q1 24	$0	$0	-$11M
Q2 24	$0	$0	-$11M
Q3 24	$0	$0	-$7M
Q4 24	$0	$0	-$1M
Q1 25	$0	$0	-$4M
Q2 25	$0	$0	-$16M
Q3 25	$0	$0	-$1M
Q4 25	$0	-$91.8K	-$4M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$12M	-$12M
Q2 22	-$12M	-$12M
Q3 22	$2M	$2M
Q4 22	-$9M	-$9M
Q1 23	-$14M	-$14M
Q2 23	-$8M	-$8M
Q3 23	-$14M	-$14M
Q4 23	-$103.8K	-$234.6K
Q1 24	-$8M	-$8M
Q2 24	-$2M	-$2M
Q3 24	-$6M	-$6M
Q4 24	-$10M	-$10M
Q1 25	-$4M	-$4M
Q2 25	-$6M	-$6M
Q3 25	$2M	$2M
Q4 25	-$1M	-$1M

Capital Expenditures

Quarter	CapEx
Q1 22	$223.8K
Q2 22	$161.8K
Q3 22	$164.5K
Q4 22	$148.3K
Q1 23	$214.4K
Q2 23	$184.7K
Q3 23	$114.6K
Q4 23	$130.8K
Q1 24	$109.2K
Q2 24	$132.1K
Q3 24	$84.9K
Q4 24	$68.8K
Q1 25	$52.6K
Q2 25	$76.9K
Q3 25	$63.4K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-8.9%
Q2 22	—	-51.3%
Q3 22	—	-37.9%
Q4 22	—	-6.6%
Q1 23	—	-12.6%
Q2 23	—	+20.3%
Q3 23	—	+33.3%
Q4 23	—	-38.1%
Q1 24	—	-9.6%
Q2 24	—	+33.1%
Q3 24	—	-35.5%
Q4 24	—	-90.5%
Q1 25	—	-65.5%
Q2 25	—	+41.6%
Q3 25	—	-85.4%
Q4 25	—	+224.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$2M	—
Q3 22	$2M	—
Q4 22	$1M	—
Q1 23	$2M	—
Q2 23	$1M	—
Q3 23	$1M	—
Q4 23	$1M	—
Q1 24	$844.0K	—
Q2 24	$897.9K	—
Q3 24	$505.6K	—
Q4 24	-$28.3K	—
Q1 25	$347.8K	—
Q2 25	$11M	—
Q3 25	$1M	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$13M	$3M	—
Q2 22	$9M	$3M	—
Q3 22	$10M	$2M	—
Q4 22	$18M	$2M	—
Q1 23	$9M	$2M	—
Q2 23	$5M	$2M	—
Q3 23	$10M	$2M	—
Q4 23	$9M	$2M	—
Q1 24	$9M	$2M	—
Q2 24	$9M	$2M	—
Q3 24	$5M	$2M	—
Q4 24	$982.9K	$728.1K	—
Q1 25	$2M	$1M	—
Q2 25	$10M	$6M	—
Q3 25	$3M	$2M	—
Q4 25	—	—	$1M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$71M	$0	$71M
Q2 22	$63M	$0	$63M
Q3 22	$68M	$0	$68M
Q4 22	$57M	$0	$57M
Q1 23	$42M	$0	$42M
Q2 23	$33M	$0	$33M
Q3 23	$24M	$0	$24M
Q4 23	$23M	$0	$23M
Q1 24	$17M	$0	$17M
Q2 24	$16M	$0	$16M
Q3 24	$15M	$0	$15M
Q4 24	$9M	$0	$9M
Q1 25	$5M	$0	$5M
Q2 25	$11M	$0	$11M
Q3 25	$34M	$0	$34M
Q4 25	$33M	$0	$33M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	5M	-0.6%	+1.0%
Q2 22	5M	+0.0%	+0.1%
Q3 22	5M	0.0%	+0.0%
Q4 22	5M	+0.4%	-0.1%
Q1 23	5M	-0.0%	+0.4%
Q2 23	5M	+0.0%	+0.4%
Q3 23	5M	+0.5%	+0.9%
Q4 23	5M	0.0%	+0.5%
Q1 24	4M	-18.6%	-18.2%
Q2 24	5M	+5.8%	-13.5%
Q3 24	5M	+6.6%	-8.2%
Q4 24	6M	+17.1%	+7.5%
Q1 25	6M	+7.3%	+41.7%
Q2 25	6M	0.0%	+34.0%
Q3 25	4M	-39.1%	-23.5%
Q4 25	4M	0.0%	-34.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	33
Q2 22	$0	33
Q3 22	$0	33
Q4 22	$0	31
Q1 23	$0	31
Q2 23	$0	31
Q3 23	$0	31
Q4 23	$0	28
Q1 24	$0	28
Q2 24	$0	28
Q3 24	$0	28
Q4 24	$0	23
Q1 25	$0	23
Q2 25	$0	23
Q3 25	$0	23
Q4 25	$0	18

Revenue / Employee